Biosplice Therapeutics - Crunchbase Company Profile & Funding
Lianzhong Technology Crunchbase Company Profile & Funding
Biosplice Therapeutics - Crunchbase Company Profile & Funding. Biosplice therapeutics has produced fresh biological insights and unique chemical equity that delivers therapeutic modulation of alternative splicing by targeting the clk/dyrk family kinases. This profile is based on publicly available information.
Lianzhong Technology Crunchbase Company Profile & Funding
Summary people technology signals & news similar companies. Its mission is to improve clinical outcomes and the quality of life for all. Companies like biosplice therapeutics include twist. Biosplice therapeutics has produced fresh biological insights and unique chemical equity that delivers therapeutic modulation of alternative splicing by targeting the clk/dyrk family kinases. Stemming from foundational discoveries in wnt pathway modulation, biosplice has elucidated novel biology linking clk/dyrk kinases to the therapeutic regulation of alternative splicing. This profile is based on publicly available information. Onal discoveries in wnt pathway modulation, biosplice has elucidated novel biology linking clk/dyrk kinases to the therapeutic regulation of alternative splicing. The company asserts that medicines that can harness this process will help cure musculoskeletal, ummune and oncological disorders. Equityzen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. Ics is an ibm and salesforce software developer and consulting company.
Summary people technology signals & news similar companies. Summary people technology signals & news similar companies. 2 age (years) $270m total funding. Explore biosplice therapeutics's investment information, scientific platforms, therapeutic approaches, indications and more here! Ics is an ict company that provides software and system products. Biosplice therapeutics has produced fresh biological insights and unique chemical equity that delivers therapeutic modulation of alternative splicing by targeting the clk/dyrk family kinases. 11 rows biosplice therapeutics has raised a total of $799m in funding over 6 rounds. Its mission is to improve clinical outcomes and the quality of life for all. List of biosplice therapeutics 's 6 funding rounds from 12 investors. Onal discoveries in wnt pathway modulation, biosplice has elucidated novel biology linking clk/dyrk kinases to the therapeutic regulation of alternative splicing. Equityzen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above.
